Alzheimer's Drug Discovery Foundation Issues RFP for Biomarker Studies

Alzheimer's Drug Discovery Foundation
Submission deadline: 
July 13, 2018

Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases; (2) enrich and stratify patient cohorts; (3) demonstrate target engagement for novel therapeutics; and (4) reliably monitor disease progression and response to treatment. Thus, additional biomarkers are needed to provide a more complete picture of the disease. To that end, the Alzheimer's Drug Discovery Foundation has issued a Request for Proposals to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. Grants of up to $300,000 over two years will be awarded in support of projects focused on the development of biomarkers previously identified in samples from well-characterized human subject. Eligible applicants include academic investigators seeking to create and support innovative biomarker programs in academic medical centers and universities, and biotechnology companies with programs dedicated to Alzheimer's disease biomarker development. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones. Letters of Intent must be received no later than July 13, 2018. Upon review, selected applicants will be invited to submit a full proposal by August 10, 2018. For complete program guidelines and proposal submission instructions, see the Alzheimer's Drug Discovery Foundation website. Link to Complete RFP